Clinical Trials Directory

Trials / Completed

CompletedNCT04116203

Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)

Dietary Fish Oil Intervention in Polycystic Ovary Syndrome

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
52 (actual)
Sponsor
University of Alberta · Academic / Other
Sex
Female
Age
18 Years – 30 Years
Healthy volunteers
Not accepted

Summary

The primary objective in this proposed study is to determine the effect of dietary fish oil supplementation compared to standard care metformin treatment, and fish oil in combination with metformin on plasma lipids and apoB-remnant lipoprotein metabolism in overweight-obese young women with PCOS.

Detailed description

Specific Objectives; 1. To determine the effect of dietary fish oil supplementation, metformin, and fish oil in combination with metformin on fasting and non-fasting plasma TG, apoB48 and apoB100-lipoprotein concentrations. 2. To determine the physiological mechanisms associated with the effect of dietary fish oil supplementation and metformin on in vivo plasma lipid and apoB-lipoprotein kinetics. We will quantitate the in vivo production and kinetics of plasma TG, apoB48 and apoB100-lipoproteins in plasma and isolated lipoprotein fractions, using established methods. 3. To explore the effects of dietary fish oil supplementation, metformin and fish oil in combination with metformin, on plasma insulin and testosterone, and the association with changes in plasma lipids and apoB-lipoprotein metabolism.

Conditions

Interventions

TypeNameDescription
DRUGMetforminManufacturer's standard 500 mg. Submission Control No.:128147
COMBINATION_PRODUCTFish Oil and MetforminCombo of 2 other arms
DIETARY_SUPPLEMENTFish OilNPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral

Timeline

Start date
2016-06-30
Primary completion
2020-11-12
Completion
2020-11-12
First posted
2019-10-04
Last updated
2025-02-28

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT04116203. Inclusion in this directory is not an endorsement.